
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.
Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and notable improvements in health markers. This success could lead...





